trial · primary record
XEN1101
Focal Onset Seizures
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 360 |
| Primary completion | 2028-03 |
| Primary endpoint | Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo. |
| Registry ID | NCT05716100 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:54.187Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05716100
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Xen1101 · compound